Dissertations / Theses on the topic 'Arzneimittelentwicklung'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 21 dissertations / theses for your research on the topic 'Arzneimittelentwicklung.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Lindenberg, Marc. "A biopharmaceutics classification scheme for the development of new drugs /." Aachen : Shaker, 2008. http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&doc_number=016726181&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA.
Full textHenke-Saipt, Alice. "Pharmakologische und toxikologische Prüfung von chemischen Stoffen und Zubereitungen an Wirbeltieren im Rahmen von Rechtsvorschriften : Art, Umfang und Einschränkungsmöglichkeiten /." Gießen : Fachverl. Köhler, 2000. http://www.gbv.de/dms/bs/toc/32898678X.pdf.
Full textKiehm, Kevin Christopher. "Development of a novel screening tool for the prediction of oral drug absorption based on surface activity profiling." Aachen Shaker, 2009. http://d-nb.info/992916844/04.
Full textNack, Ursula. "Strategien zur Impfstoffentwicklung gegen das humane Immundefizienz-Virus Typ 1 (HIV-1)." [S.l.] : [s.n.], 2003. http://deposit.ddb.de/cgi-bin/dokserv?idn=968902316.
Full textGanz, Matthias. "Herstellung partikulärer Formulierungen für rekombinante Proteine mittels Wirbelschicht." München Verl. Dr. Hut, 2007. http://d-nb.info/987775928/04.
Full textBuchholz, Kathrin. "Redoxnetzwerke des Malariaerregers Plasmodium Validierung von Schlüsselenzymen für neue chemotherapeutische Ansätze." Giessen VVB Laufersweiler, 2008. http://d-nb.info/994756232/04.
Full textLindenberg, Marc. "A biopharmaceutics classification scheme for the development of new drugs." Aachen Shaker, 2007. http://d-nb.info/987761897/04.
Full textIlgin, Yasemin. "Health care expenditures, innovation, and demographic change." Frankfurt, M. Berlin Bern Bruxelles New York, NY Oxford Wien Lang, 2007. http://d-nb.info/989527727/04.
Full textGreindl, Alexandra [Verfasser]. "Zell- und molekularbiologische Untersuchungen eines EPO-mimetischen Peptides während der präklinischen Phase der Arzneimittelentwicklung / Alexandra Greindl." Aachen : Hochschulbibliothek der Rheinisch-Westfälischen Technischen Hochschule Aachen, 2010. http://d-nb.info/1015148964/34.
Full textBusse, Kerstin Elisabeth. "Charakterisierung der Wechselwirkungen zwischen schwerlöslichen Arzneistoffen und nichtionischen Polymeren unterschiedlicher Hydrophilie zur Entwicklung peroral applizierbarer Arzneiformen /." [S.l. : s.n.], 1999. http://www.gbv.de/dms/bs/toc/303284188.pdf.
Full textKoitka, Matthias. "Isolierung, Identifizierung und Inhibition von Esterasen aus Ratten- und Hundeserum zur Stabilisierung von Serumproben ex vivo im Rahmen der präklinischen Arzneimittelentwicklung." Berlin mbv, 2009. http://d-nb.info/993024033/04.
Full textAmbroz, Kristjan. "Estimating new product uptake with the use of system dynamics /." Table on contents, 2009. http://aleph.unisg.ch/hsgscan/hm00231776.pdf.
Full textSlopianka, Markus [Verfasser], Ulrike [Gutachter] Holzgrabe, Angela [Gutachter] Mally, and Oliver [Gutachter] Scherf-Clavel. "Evaluation von Gallensäuren als Biomarker für Lebertoxizität in der präklinischen Arzneimittelentwicklung / Markus Slopianka ; Gutachter: Ulrike Holzgrabe, Angela Mally, Oliver Scherf-Clavel." Würzburg : Universität Würzburg, 2020. http://d-nb.info/1211328392/34.
Full textTatzel, Stephan. "Modellierung von Cytochrom P450-Monooxygenasen." [S.l. : s.n.], 2008. http://nbn-resolving.de/urn:nbn:de:bsz:93-opus-34577.
Full textKoitka, Matthias [Verfasser]. "Isolierung, Identifizierung und Inhibition von Esterasen aus Ratten- und Hundeserum zur Stabilisierung von Serumproben ex vivo im Rahmen der präklinischen Arzneimittelentwicklung / Matthias Koitka." Berlin : Freie Universität Berlin, 2009. http://d-nb.info/1023581582/34.
Full textKowalik, Dorota [Verfasser], Jerzy [Akademischer Betreuer] [Gutachter] Adamski, and Johannes [Gutachter] Buchner. "SDR- und AKR- Enzyme in der Arzneimittelentwicklung und Suche nach der Funktion neuer SDR-Enzyme / Dorota Kowalik ; Gutachter: Jerzy Adamski, Johannes Buchner ; Betreuer: Jerzy Adamski." München : Universitätsbibliothek der TU München, 2017. http://d-nb.info/1127225286/34.
Full textGelmedin, Verena Magdalena. "Targeting flatworm signaling cascades for the development of novel anthelminthic drugs." kostenfrei, 2008. http://www.opus-bayern.de/uni-wuerzburg/volltexte/2009/3333/.
Full textSlopianka, Markus. "Evaluation von Gallensäuren als Biomarker für Lebertoxizität in der präklinischen Arzneimittelentwicklung." Doctoral thesis, 2020. https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-204627.
Full textDrug-induced liver injury (DILI) remains a significant challenge in preclinical drug development. Nonclinical studies provide an opportunity to correlate the biochemical and morphological findings; however, liver injury is often complex and heterogeneous, confounding the ability to relate biochemical changes to specific, histopathological patterns of liver injury. The diagnostic performance of the available hepatobiliary markers, such as alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT) or alkaline phosphatase (APh), for specific manifestations of liver injury, is often limited and insensitive, e.g. minimal to slight liver pathology might not result in changes to the serum marker. Furthermore, histopathological findings in the liver can occur without there being significant changes in the serum markers and vice versa. Although histopathology is the gold standard, its invasive nature makes it unsuitable for monitoring liver injury in toxicological and non-clinical studies. In recent years, study results of bile acid profiling, using liquid chromatography-tandem mass spectrometry (LC-MS/MS), indicated diagnostic potential regarding the detection of hepatotoxicity. This work aims to establish bile acid profiling in preclinical drug development and to demonstrate that bile acids can provide a valuable contribution to characterizing liver injury in preclinical safety diagnostics. For this purpose, a quantitative LC-MS/MS method was established and validated, in order to analyze 20 different endogenous bile acids in rats. The quantitative analysis enabled the selective determination of primary, conjugated and secondary bile acids. 2 MRM-transitions for qualitative and quantitative analysis were used for the quantification of the individual bile acids. Twenty bile acid reference standards were used for the calibration range. A seven-point calibration, in ascending concentration, was performed to quantify the absolute endogenous bile acid concentrations. Ten isotopically labeled internal standards were employed in the analyses to compensate for matrix effects. The reproducibility of the current measurements was monitored by quality controls (QCs) inserted into three different concentration ranges. Bile acid profiling was performed by LC-MS/MS of plasma and liver tissue of rats that had been treated with different hepatotoxins. The results of the bile acid profiling and histopathological evaluation revealed correlation between bile acid profiles and histopathological graded liver toxicity, e.g., the quantitative analysis and histopathological examination showed that macrovesicular steatosis was induced in the livers of male rats which had been treated with amitriptyline for 14 days. Classic serum markers, such as ALAT, ASAT, and gamma-glutamyltransferase (γGT), were unable to detect this specific manifestation of liver injury. In contrast, the concentrations of glycine-conjugated bile acids Summary increased while there was a parallel decrease in the levels of taurine-conjugated bile acids in the treated rats’ liver tissue. At the same time, there was a significant increase in the concentration of primary bile acids, CA and CDCA, in plasma of treated rats. Different bile acid profiles were observed following methapyrilene-induced liver cell necrosis with hepatobiliary damage. After a 14-day treatment phase with 80 mg/kg body weight methapyrilene, the concentrations of 11 bile acids increased in liver tissue of treated animals. At the same time, the levels of all 20 individual bile acids increased in plasma of treated rats. In addition to the quantitative analysis of bile acids with LC-MS/MS, the expression of specific genes associated with bile acid biosynthesis, and the transport and regulation of bile acid homeostasis, was analyzed using multiplex analysis of targeted mRNA. The increased expression of efflux transporter genes belonging to the multidrug resistance-related protein (MRP) family, indicated an increase in the efflux transport of bile acids into blood, and corresponded to increased bile acid concentrations in the plasma of treated rats. Furthermore, bile acid profiles originated from the animal studies, were used as reference to evaluate bile acid profiles regarding liver toxicity on a liver cell-based biological system. In vitro experiments were performed using primary rat hepatocytes between two collagen matrices (sandwich cultivation). This traditional in vitro model is used to study of hepatobiliary transport alterations (e.g., Bile Salt Export Pump, BSEP). Bile acid profiling of the cell culture supernatants demonstrated that the primary hepatocytes produced conjugated bile acids. Incubation with primary bile acids resulted in an improvement of the in vitro system by producing conjugated bile acids, in addition to those already existed. Exposure to troglitazone and methapyrilene resulted in changes in the hepatocytes’ bile acid homeostasis. In the in vivo experiments, methapyrilene treatment induced necrosis and hepatobiliary damage in the treated rats. There was a substantial increase in the concentration of plasma bile acids in the methapyrilene treatment group (including GCA and TCA), which correlated with the histopathological findings. Based on these data and the pharmacokinetic properties of methapyrilene, a study design was developed that used rat hepatocytes in sandwich cultures to provide an initial estimate of bile acid concentration changes in the in vitro test system. There was an increase in GCA and TCA concentrations in the cell culture medium from day 8 of the methapyrilene treatment. Therefore, the in vitro test system may have the potential to support or even reduce animal studies for evaluating hepatotoxicity. Bile acid profiling in male and female rats is a suitable method for detecting and differentiating liver injury. The technology can be used flexibly and can support already established test procedures, such as the determination of serum markers in clinical chemistry and histopathology. Summary Thus, bile acid profiling has the potential to fill the gap in the detection and characterization of hepatotoxicity, as part of the evaluation of preclinical drug candidates
Arndt, Markus. "Porphyrin-Platin(II)-Komplexe in der Tumortherapie : systematische Synthese und Testung multifunktionaler Wirkstoffe /." 1998. http://www.gbv.de/dms/bs/toc/301413444.pdf.
Full textSchweizer, Steffen. "Erstellung eines Präformulierungskonzeptes für mittelständische Pharmaunternehmen unter besonderer Berücksichtigung der physikalisch-chemischen Eigenschaften neuer Arzneistoffe, dargestellt am Beispiel der NMDA-Antagonisten MRZ 2/579 und MRZ 2/576 /." 2001. http://www.gbv.de/dms/bs/toc/341799610.pdf.
Full textZiegenbalg, Oliver. "Einsatzmöglichkeiten der Mikrokalorimetrie bei der Formulierungsentwicklung in der Veterinärpharmazie /." 2005. http://www.gbv.de/du/services/toc/bs/488081351.
Full text